Pathologic and oncologic outcomes in locally advanced gastric cancer with neoadjuvant chemotherapy or chemoradiotherapy

Yonsei Medical Journal

Volumn 54, Issue 4, 2013, Pages 888-894

  An, Ji Yeong ^a   Kim, Hyoung Il ^a   Cheong, Jae Ho ^a   Hyung, Woo Jin ^a   Kim, Choong Bae ^a   Noh, Sung Hoon ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Gastrectomy; Gastric cancer; Neoadjuvant chemoradiotherapy; Neoadjuvant chemotherapy; Pathologic response; Prognosis

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; TUMOR MARKER;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GASTRECTOMY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OPERATION DURATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOLOGY; POSTOPERATIVE COMPLICATION; PREDICTIVE VALUE; PREOPERATIVE TREATMENT; RETROSPECTIVE STUDY; STOMACH CANCER; TUMOR RECURRENCE;

GASTRECTOMY; GASTRIC CANCER; NEOADJUVANT CHEMORADIOTHERAPY; NEOADJUVANT CHEMOTHERAPY; PATHOLOGIC RESPONSE; PROGNOSIS;

AGED; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84878253550     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2013.54.4.888     Document Type: Article

References (13)

1. Rohatgi PR, Mansfield PF, Crane CH, Wu TT, Sunder PK, Ross WA, et al. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer 2006;107: 1475-82.
2. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004;22:2774-80.
3. Becker K, Langer R, Reim D, Novotny A, Meyerzum Buschenfelde C, Engel J, et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg 2011;253:934-9.
4. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005;23:1237-44.
5. Nakajima T. Gastric cancer treatment guidelines in Japan. Gastric Cancer 2002;5:1-5.
6. Sobin LH, Wittekind CH. TNM Classification of Malignant Tumours. 7th ed. International Union Against Cancer (UICC). New York: Wiley; 2009.
7. An JY, Cheong JH, Hyung WJ, Noh SH. Recent evolution of surgical treatment for gastric cancer in Korea. J Gastric Cancer 2011;11:1-6.
8. Lee JH, Kim KM, Cheong JH, Noh SH. Current management and future strategies of gastric cancer. Yonsei Med J 2012;53:248-57.
9. Sym SJ, Chang HM, Ryu MH, Lee JL, Kim TW, Yook JH, et al. Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer. Ann Surg Oncol 2010;17:1024-32.
10. Lordick F, Stein HJ, Peschel C, Siewert JR. Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 2004;91:540-51.
11. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
12. Stahl M, Vanhoefer U, Stuschke M, Walz MK, Müller C, Wilke H. Pre-operative sequential chemo-and radiochemotherapy in locally advanced carcinomas of the lower oesophagus and gastro-oesophageal junction. Eur J Cancer 1998;34:668-73.
13. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851-6.